Though previous studies mentioned that immunohistochemical (IHC) identification of p16INK4a could be a biomarker to predict the outcomes of cervical cancer lesions, the predominance of comparing as a biomarker along with HPV genotyping was not fully elucidated. The gene discussed is CDKN2A; the disease is cervical carcinoma.